08:36 AM EDT, 05/31/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) on Friday reported "positive results" from phase 3 studies of its investigational drug donidalorsen for the treatment of hereditary angioedema, or HAE, with a more than 90% improvement in attack rates after one year for both monthly and bi-monthly dosing.

Patients switching from previous treatments saw a 62% further reduction in attack rates, with 84% preferring donidalorsen, the company said. The drug demonstrated a favorable safety profile in the studies, the company said.

Ionis Pharmaceuticals ( IONS ) said it plans to seek regulatory approval for donidalorsen as a treatment for HAE.

HAE is a rare, potentially life-threatening genetic disorder causing recurrent severe swelling in various body parts, including the hands, feet, genitals, stomach, face, and throat.

Shares of the company were 1% lower in Friday premarket activity

Price: 37.00, Change: +0.45, Percent Change: +1.23